Citius Oncology
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell CTOR and other ETFs, options, and stocks.About CTOR
Citius Oncology, Inc. is a biopharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.
CEOLeonard L. Mazur
CEOLeonard L. Mazur
Employees—
Employees—
HeadquartersCranford, New Jersey
HeadquartersCranford, New Jersey
Founded2021
Founded2021
Employees—
Employees—
CTOR Key Statistics
Market cap89.04M
Market cap89.04M
Price-Earnings ratio-3.11
Price-Earnings ratio-3.11
Dividend yield—
Dividend yield—
Average volume275.55K
Average volume275.55K
High today$1.11
High today$1.11
Low today$1.05
Low today$1.05
Open price$1.11
Open price$1.11
Volume86.68K
Volume86.68K
52 Week high$6.19
52 Week high$6.19
52 Week low$0.5506
52 Week low$0.5506
Stock Snapshot
The current Citius Oncology(CTOR) stock price is $1.05, with a market capitalization of 89.04M. The stock trades at a price-to-earnings (P/E) ratio of -3.11.
During the trading session on 2026-01-18, Citius Oncology(CTOR) shares reached a daily high of $1.11 and a low of $1.05. At a current price of $1.05, the stock is +0.2% higher than the low and still -5.2% under the high.
Trading activity shows a volume of 86.68K, compared to an average daily volume of 275.55K.
The stock's 52-week range extends from a low of $0.55 to a high of $6.19.
The stock's 52-week range extends from a low of $0.55 to a high of $6.19.
People also own
Based on the portfolios of people who own CTOR. This list is generated using Robinhood data, and it’s not a recommendation.